Ascendis Pharma (Denmark)

company in Copenhagen, Denmark

ASND Nasdaq ISIN US04351P1012 SEC CIK 1612042 LEI 549300B66JN3W3J8GH73
Follow Ascendis Pharma (Denmark) Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 EUR · IFRS
Revenue, last quarter €247.5M +42.3% vs same quarter last year
Net income −€33.6M +12.8% vs same quarter last year
EPS, diluted -
Operating cash flow €73.4M +184.2% vs same quarter last year
Revenue by quarter
€95.9M
€36M
€57.8M
€173.9M
€101M
€158M
€213.6M
€247.5M
Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−€1B−€500M€0€500M€1BFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€720.1M−€228M
FY24€363.6M-
FY23€266.7M−€481.4M
FY22€51.2M−€583.2M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2586.8%−18.9%−31.7%
FY2487.8%−76.7%-
FY2383.4%−170.8%−180.5%
FY2276.3%−1097.9%−1139.6%
Returned to shareholdersDividends paid and shares bought back
€0€50M€100M€150MFY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25€17.4M
FY24-
FY23€0
FY22€105.3M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ascendis Pharma (Denmark)
  • Healthcare median
−1500%−1000%−500%0%FY22FY23FY24FY25
Show the numbers
YearAscendis Pharma (Denmark)Healthcare median
FY25−31.7%−30.6%
FY24-−47%
FY23−180.5%−58%
FY22−1139.6%−80.4%